<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02145260</url>
  </required_header>
  <id_info>
    <org_study_id>2014P000629</org_study_id>
    <nct_id>NCT02145260</nct_id>
  </id_info>
  <brief_title>Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients</brief_title>
  <official_title>Randomized Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intra-dialytic hypotensive (IDH) events can be defined as an abrupt decline in blood pressure
      that cause symptoms and/or require an intervention. They are common, affecting up to one
      third of maintenance HD sessions. Detrimental associations include: development of myocardial
      stunning, cerebral hypo-perfusion, vascular access thrombosis and greater mortality.

      Rapid solute removal by HD generates temporary osmotic gradients between the intra-vascular
      and intra-cellular compartments, promoting trans-cellular fluid movement and resultant
      hypotension. Manipulation of osmotic gradients, e.g. using higher dialysate sodium (DNa), may
      ameliorate excess SBP decline during HD.

      This study aims to assess the effects of higher (142 mmol/L) versus lower (138 mmol/L)
      dialysate sodium (DNa) use in adult chronic hemodialysis patients admitted to hospital on
      intra-dialytic blood pressure and biomarkers of cardiac ischemia.

      The investigators will randomly assign subjects to higher versus lower DNa during their
      hospital stay, up to a maximum of six HD sessions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Magnitude of intra-dialytic decline in systolic blood pressure</measure>
    <time_frame>Average decline in systolic blood pressure will be measured up to a maximum of six inpatient HD sessions, occurring over a two-week time period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pre-dialysis high-sensitivity troponin I</measure>
    <time_frame>The change in pre-dialysis high sensitivity troponin I concentrations will be measured between the first and second inpatient hemodialysis sessions, occuring over a period of three days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Intra-dialytic Hypotension</condition>
  <arm_group>
    <arm_group_label>Lower dialysate sodium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dialysate sodium concentration of 138 mmol/L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher dialysate sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dialysate sodium concentration of 142 mmol/L</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lower dialysate sodium (138 mmol/L; using Renasol hemodialysis concentrate)</intervention_name>
    <description>A lower dialysate sodium will bes used in the active comparator arm (138 mmol/L)</description>
    <arm_group_label>Lower dialysate sodium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Higher dialysate sodium (142 mmol/L; using Renasol hemodialysis concentrate)</intervention_name>
    <description>A higher dialysate sodium will be used in the experimental arm (142 mmol/L)</description>
    <arm_group_label>Higher dialysate sodium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic HD (&gt;90 days)

          -  Age â‰¥18y

          -  Informed consent

          -  First admission during study period.

        Exclusion Criteria:

          -  Use of pressors

          -  Pre-dialysis serum sodium &lt;=128mmol/L or &gt; 145 mmol/L

          -  Pre-dialysis SBP &gt;180 mmHg

          -  Intensive care stay earlier in admission

          -  Expected length of stay &lt;24 hours (e.g. admission for HD access procedure)

          -  Acute coronary syndrome within seven days

          -  Acute stroke

          -  Institutionalized individuals

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Finnian Mc Causland, MB, MMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Finnian Mc Causland, MB, MMSc</last_name>
    <email>fmccausland@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Finnian Mc Causland, MB, MMSc</last_name>
      <email>fmccausland@partners.org</email>
    </contact>
    <investigator>
      <last_name>Sushrut Waikar, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2014</study_first_submitted>
  <study_first_submitted_qc>May 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2014</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Finnian McCausland</investigator_full_name>
    <investigator_title>Instructor in Medicine, Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <keyword>Hypotension</keyword>
  <keyword>Hospitalization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dialysis Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

